Typhoid Vaccine Developments (2025): latest developments in typhoid vaccines as of 2025, based on recent clinical trials and global health initiatives:
Latest Typhoid Vaccine Developments (2025)
Trivalent Salmonella Conjugate Vaccine (TSCV)
- A new investigational vaccine called the Trivalent Salmonella Conjugate Vaccine (TSCV) has shown promising results in a Phase 1 human trial.
- Developed by researchers at the University of Maryland School of Medicine and Bharat Biotech, TSCV is designed to protect against:
- Typhoid fever (Salmonella typhi)
- Invasive non-typhoidal Salmonella (iNTS) infections, which cause severe bloodstream infections, especially in children in sub-Saharan Africa.
- The vaccine uses sugar molecules from the outer coating of the bacteria, conjugated to proteins that enhance immune response.
- In the trial, 22 healthy adults received either low or high doses of TSCV. Results showed:
- Strong immune responses
- Good safety and tolerability
- Researchers believe this could be a game-changer for regions facing dual burdens of typhoid and iNTS.
Global Rollout and Integration
- Countries such as Pakistan, Bangladesh, and Nepal continue to expand their use of Typbar-TCV, with measurable reductions in typhoid incidence.
- The Coalition Against Typhoid emphasizes the urgency of deploying TCVs alongside WASH (Water, Sanitation, and Hygiene) interventions to curb antibiotic resistance and disease spread Take on Typhoid.
